Danielle Marie Brander, MD

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, Durham, NC 27710
Phone (919) 668-1000
Email address danielle.brander@duke.edu
In Their Words

Education and Training

  • Resident, Internal Medicine, Duke University School of Medicine, 2007 - 2010
  • M.D., Duke University School of Medicine, 2007

Grants

Publications

Mato, Anthony R., Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle Brander, Mazyar Shadman, et al. “Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.” Clin Cancer Res 26, no. 14 (July 15, 2020): 3589–96. https://doi.org/10.1158/1078-0432.CCR-19-3815.

PMID
32198151
Full Text

Sung, Anthony D., Shekeab Jauhari, Sharareh Siamakpour-Reihani, Arati V. Rao, Janet Staats, Cliburn Chan, Everett Meyer, et al. “Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.” Am J Hematol 95, no. 6 (June 2020): 662–71. https://doi.org/10.1002/ajh.25781.

PMID
32162718
Full Text

Eyre, Toby A., Lindsey E. Roeker, Christopher P. Fox, Satyen H. Gohill, Renata Walewska, Harriet S. Walter, Francesco Forconi, et al. “The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.” Br J Haematol 188, no. 6 (March 2020): 918–23. https://doi.org/10.1111/bjh.16271.

PMID
31682002
Full Text

Eichenberger, Emily M., Jennifer Saullo, Danielle Brander, Shih-Hsiu Wang, John R. Perfect, and Julia A. Messina. “A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy.” Med Mycol Case Rep 27 (March 2020): 17–21. https://doi.org/10.1016/j.mmcr.2019.12.007.

PMID
31879587
Full Text

Weinberg, J Brice, Danielle M. Brander, Dale J. Christensen, and Daphne R. Friedman. “Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al.” Br J Haematol 186, no. 4 (August 2019): 637. https://doi.org/10.1111/bjh.15934.

PMID
31044417
Full Text

Davids, Matthew S., Danielle M. Brander, Haesook T. Kim, Svitlana Tyekucheva, Jad Bsat, Alexandra Savell, Jeffrey M. Hellman, et al. “Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.” Lancet Haematol 6, no. 8 (August 2019): e419–28. https://doi.org/10.1016/S2352-3026(19)30104-8.

PMID
31208944
Full Text

Roeker, Lindsey E., Christopher P. Fox, Toby A. Eyre, Danielle M. Brander, John N. Allan, Stephen J. Schuster, Chadi Nabhan, et al. “Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.” Clin Cancer Res 25, no. 14 (July 15, 2019): 4264–70. https://doi.org/10.1158/1078-0432.CCR-19-0361.

PMID
31004001
Full Text

Mato, Anthony R., Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, et al. “A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.” Blood Adv 3, no. 10 (May 28, 2019): 1568–73. https://doi.org/10.1182/bloodadvances.2019000180.

PMID
31101647
Full Text

Brander, Danielle M., Daphne R. Friedman, Alicia D. Volkheimer, Dale J. Christensen, Laura Z. Rassenti, Thomas J. Kipps, Eross Guadalupe, et al. “SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.” Br J Haematol 184, no. 4 (February 2019): 605–15. https://doi.org/10.1111/bjh.15677.

PMID
30443898
Full Text

Pages